Welcome to the 17th Annual Scientific Conference of the Society on NeuroImmune Pharmacology.

We are pleased to publish the abstracts from the 17th Annual Conference of the Society on NeuroImmune Pharmacology (SNIP) in the *Journal of Neuroimmune Pharmacology*. This is the second year that the abstracts from our conference are published in their entirety. We are most pleased that Springer has agreed to continue providing open access to these abstracts. On behalf of the SNIP, we especially recognize the continued support of Dr. Howard E. Gendelman and Ms. Robin Taylor, the editor‐in‐chief and managing editor, respectively, of the *Journal of Neuroimmune Pharmacology*, and Ann Avouris, Springer US, in seeing this abstract book to fruition.

The goal of the 2011 SNIP Conference---April 5--10, 2011, at the Hilton Clearwater Beach Resort, Clearwater Beach, FL, USA---will be to assess the role of drugs of abuse in modulating neuroimmune responses and to elucidate the physiological consequences of such alterations in infectious disease processes, such as HIV-1 infection, to garner knowledge helpful in the development of therapeutics.

The society believes that young investigators are key to the continuation and expansion of our field of neuroimmune pharmacology. Thus, we have dedicated four events in this year's conference to young scientists. The 17th SNIP Conference will open on Wednesday evening (April 6) with the Young Investigator Poster Session, which highlights recent research accomplishments by young researchers. This poster session will be followed by a special "Meet the Mentors" dinner, attended by the young investigators who are presenting their work at the conference as well as mentors from academia, industry, and the National Institutes of Health (NIH), who have influenced the field of neuroimmune pharmacology. Larry Robinson, Ph.D., Provost at Seton Hall University, will be the featured speaker at this dinner and will give a lecture on the value of mentoring in promoting career development of young investigators. In addition to the Young Investigator Poster Session, a general poster session will also be held on Thursday, April 7. The third event dedicated to young investigators will be the Young Investigators' Symposium, which will take place on Friday, April 8. The aim of this symposium will be to highlight the work of three postdoctoral and three predoctoral researchers selected by the Young Investigator Travel Award Committee, from the pool of over 40 abstracts, based on their quality and research accomplishments. The Bill Narayan Memorial Lecture, sponsored by Dr. Gendelman in memory of his mentor, the late Dr. Bill Narayan, will be the fourth event dedicated to young investigators. This lecture, which will be given on Saturday, April 9, will emphasize the essential role that reciprocity plays in the mentor--mentee relationship, and will serve as an example of the important role of the mentor in the professional and intellectual growth of young investigators.

This year's conference will include two plenary lectures. On Thursday, April 7, Horace H. Loh, Ph.D. will present the first conference plenary lecture on receptor engineering in the treatment of pain and the search for the "ideal analgesic." Dr. Loh's lecture will set the tone for the conference in that it will highlight the integration of pharmacology into the neuroimmunology of health and disease. Our second plenary lecture will be presented by Steve Nelson, M.D. (Dean, Louisiana State University School of Medicine) at the opening session on Saturday, April 9. Dr. Nelson will describe the nexus between alcohol, immunosuppression, and HIV-1 infection. His presentation will highlight the relationship between substance addiction and HIV-1 neurocognitive deficits, and will shed light on the impact of these disorders on stem cell biology. This plenary lecture will set the stage for symposia V, VI, and VII to follow.

There will be a total of seven symposia presented at the conference. The first two symposia will address important issues on drugs of abuse and neuroAIDS. Symposium I entitled, "Neuroimmune Interactions---The New Frontier for Drugs of Abuse and their Endogenous Ligands," organized by Martin Adler, Ph.D. and Toby Eisenstein, Ph.D. (Temple University School of Medicine), will concentrate on drugs of abuse and their endogenous ligand interactions with the neuroimmune system. Toby Eisenstein, as the current society president, will open the symposium session with a discussion on our current understanding of the impact that drugs of abuse have on the neuroimmune axis. Kevin Tracey, M.D. (Feinstein Institute for Medical Research) will be the keynote speaker and will talk on the role of cholinergic anti-inflammatory pathways and innate immunity. Next, Lynn Kirby, Ph.D. (Temple University School of Medicine) will report on the propensity of chemokines to act as neuromodulators, and finally, Virginia Sanders, Ph.D. (The Ohio State University College of Medicine) will discuss the effects of the sympathetic nervous system, catecholamines, and norepinephrine on immune function through actions mediated by adrenergic receptors.

Symposium II, organized by Guy Cabral, Ph.D. (Virginia Commonwealth University School of Medicine) and Sabita Roy, Ph.D. (University of Minnesota), will focus on the modulation of the peripheral immune system by drugs of abuse and HIV-1. The symposium keynote speaker will be Satya Dandekar, Ph.D. (University of California at Davis), who will talk on the gut, germs, and HIV pathogenesis of immune and neurological diseases. Lena Al-Harthi, Ph.D. (Rush University Medical Center) will follow with a presentation on the role of T cell activation and T cell subsets in anti-HIV immunity. Tom Molitor, Ph.D. (University of Minnesota) will then address the effects of drug abuse on maternal immunity and its influence on neonatal immune development. Two young investigators will also speak at this symposium. Honghong Yao, Ph.D. (University of Nebraska Medical Center) will address the implications of increased vascular permeability on the induction of platelet-derived growth factor mediated by cocaine, and Li Liu, Ph.D. (University of Hong Kong, SAR, People's Republic of China) will address the effects of the cannabinoid, delta-9-tetrahydrocannabinol, on SIVmac251 infection in Chinese Macaque monkeys. The inclusion of Drs. Yao and Liu in this symposium is intended to encourage junior investigators to give oral presentations at major symposia, and is in keeping with the mission of the society to promote the professional development of young investigators.

These first two symposia will be followed by a special session that will focus on teaching and learning in the field of Neuroimmune Pharmacology. This special session will be co-chaired by Thomas J. Rogers, Ph.D. (Temple University School of Medicine) and Tom Molitor, Ph.D. (University of Minnesota College of Veterinary Medicine), and will include invited talks on the topic as well as a presentation by Howard E. Gendelman, M.D. (University of Nebraska Medical Center) on "Video Research Coming of Age."

Symposia III and IV will encompass current therapeutic approaches to managing neuropsychiatric and neurodegenerative disorders stemming from AIDS and drugs of abuse. Symposium III, organized by Jag Khalsa, Ph.D. \[National Institute on Drug Abuse (NIDA)\] and Michael Roth, M.D. (UCLA), will be more clinical in nature and will address neuropsychiatric complications of infectious diseases and substances of abuse. Dave Thomas, M.D. (Johns Hopkins University School of Medicine) will begin the symposium with a presentation on the natural history of the HIV-1 and hepatitis C (HCV) viruses. Glen Treisman, M.D. (Johns Hopkins University School of Medicine) will then speak about the management of neuropsychiatric complications of infection, particularly HIV and HCV infections. The final speaker of this symposium will be Sussana Naggie, M.D. (Duke University School of Medicine), who will discuss possible interventional agents for HIV and HCV.

Symposium IV has been organized by Abraham P. Bautista, Ph.D. \[National Institute on Alcohol Abuse and Alcoholism (NIAAA)\] and Jeymohan Joseph, Ph.D. \[National Institute of Mental Health (NIMH)\]. A presentation by Ru-Band Lu, M.D. (National Cheng Kong University, Taiwan) will focus on genetic validation of the subtypes of alcoholism. The role of neuroimmune signaling molecules as related to the neuropathology of fetal alcohol spectrum disorders then will be presented by Paul Drew, Ph.D. (University of Arkansas). The focus of this symposium then will broaden from alcohol-specific topics to therapeutic strategies targeting neuroimmune modulation, and a discussion of therapeutic stem cell approaches to mitigate brain inflammatory-derived neurodegenerative disorders. These final two topics will be presented by Adron Harris, Ph.D. (University of Texas) and Jialin Zheng, M.D. (University of Nebraska Medical Center), respectively.

Following this symposium, a luncheon NIH workshop has been organized by David Shurtleff, Ph.D. (NIDA), Jeymohan Joseph, Ph.D. (NIMH), and Abraham P. Bautista, Ph.D. (NIAAA). This workshop will be presented by officers from NIDA, NIMH, NIAAA, and the Office of the Center of Scientific Review at NIH. Each of the NIH presenters will share information on new program initiatives at NIH and provide insight on grant writing and the grant review process.

The final three symposia will focus on the relationship between substance addiction and HIV-1 neurocognitive deficits, and will discuss the impact that these disorders has on stem cell biology. Symposium V, "Cocaine and HIV-1 Interplay: Molecular Mechanisms of Action and Addiction," co-chaired by Norman Haughey, Ph.D. (Johns Hopkins School of Medicine) and Michal Toborek, M.D., Ph.D. (University of Kentucky School of Medicine), will focus on the action and addictive roles of cocaine. This symposium will commence with a lecture by Tsung-Ping Su, Ph.D. (NIDA/NIH) on molecular and inter‐organelle signaling in disease. Other speakers in this symposium include John Wang, Ph.D. (University of Missouri--Kansas School of Medicine), who will speak on the molecular neurobiology of drug addiction, Gayle Baldwin, Ph.D. (UCLA), who will address the pros and cons of mouse/human chimera models on the occurrence of cocaine and HIV-1 co‐morbidity, and Avi Nath, M.D. (National Institute of Neurological Disorders and Stroke), who will present his work regarding fulminant encephalopathy in HIV-infected cocaine users.

Following Symposium V, the Bill Narayan Memorial lecture will be presented by Shilpa Buch, Ph.D. (University of Nebraska Medical Center). David Volsky, Ph.D. (Columbia University School of Medicine) will introduce Dr. Buch, who will talk on the interplay of HIV infection and cocaine abuse in HIV-associated neurocognitive disorders.

Symposium VI, "HIV-Associated Neurocognitive Disorders (HAND) and Drug Abuse," will focus more specifically on HAND and drug abuse. Co-chairs Linda Chang, M.D. (University of Hawaii) and Mahendra Kumar, Ph.D. (Miller School of Medicine, University of Miami) have selected Bob Heaton, Ph.D. (University of California at San Diego) to give the lecture on HAND in the pre-CART and CART eras. Following this presentation, Eileen Martin, Ph.D. (University of Illinois) will speak on NeuroAIDS and substance use disorders, and Marilou Andres, Ph.D. (University of Hawaii) will present her results on the effects of the APOE-epsilon4 allele on brain functioning and structure in HIV patients. The final lecture of this symposium will be given by Valerie Wojna, M.D. (University of Puerto Rico), who will discuss challenges presented in the diagnosis of HAND in a group of Hispanic, HIV-seropositive females.

The conference will conclude with symposium VII, "The Consequences of Substance Abuse and HIV on Stem Cell Biology." Changhau Cui, Ph.D. (NIAAA/NIH) and Kurt Hauser, Ph.D. (Virginia Commonwealth University School of Medicine) have organized this symposium to include lectures on the effects of opiates and alcohol on major brain structures such as the CNS and hippocampus. The presenters for this symposium will be Pamela Knapp, Ph.D. (Virginia Commonwealth University School of Medicine), Amelia Eisch, Ph.D. (UT Southwestern Medical Center at Dallas), Ping Zhang, Ph.D. (Louisiana State University Health Sciences Center), and Pankaj Seth, Ph.D. (National Brain Research Centre, India).

In summary, the meeting will focus on disseminating new knowledge in the convergent areas of neuroAIDS and drug abuse, professional development of young investigators, active engagement of international investigators, and integration of fundamental basic science concepts and their clinical translation. The individual presentations range from basic science topics, to studies involving animal models for evaluation of infectious disease mechanisms and treatment modalities, to the study of human populations (including minority and female populations) and the effects of HIV in those populations, and finally to the development of drugs and other treatment modalities as a means of combating HIV infection.

The Hilton Clearwater Beach Resort conference site is conveniently located 20 min from the St. Petersburg/Clearwater International Airport and a half hour from Tampa International Airport, providing flexibility with flights. Just steps away, the Clearwater Beach Marina offers fishing, snorkeling, and dolphin-watching charters, and Pier 60 holds a nightly celebration in honor of the breathtaking Gulf sunset. Restaurants and shops are a short walking distance from the conference center.

Again, welcome to the 17th Annual Conference of the Society on NeuroImmune Pharmacology.
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